文献速递胃肠外科

中低位局部进展期直肠癌新辅助治疗后转移淋巴结空间分布特征及临床意义

[Spatial distribution characteristics and clinical significance of metastatic lymph nodes after neoadjuvant therapy for locally advanced mid-low rectal cancer].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2026-10-29

该回顾性病例系列分析纳入97例接受新辅助治疗并根治性切除的中低位局部进展期直肠癌患者,按标准化三站方案送检淋巴结。结果显示25.8%患者仍有淋巴结转移,且集中于S1和S2站,无S3站转移;S2站转移者无病生存显著劣于S1站。转移淋巴结部位是DFS的预后因素。

要点

  • 新辅助治疗后25.8%的中低位LARC患者仍存在淋巴结转移,主要局限于S1和S2站。
  • ypT3~4期患者淋巴结转移率38.5%,高于ypT1~2期的14.3%和ypT0期的5.9%(P=0.003)。
  • S2站转移者5年DFS率38.9%,显著劣于S1站转移者(约100%),转移部位是DFS预后因素。

核心结论

  • 中低位LARC患者新辅助治疗后淋巴结转移率降低,转移主要集中于S1和S2区域,无S3站转移。
  • 转移淋巴结分布位置是患者DFS的潜在预后因素,可考虑纳入TNM分期系统以改良预后评估。

研究设计与样本

  • 本研究为回顾性病例系列分析,纳入2016年1月至2025年6月单一治疗组收治的97例中低位LARC患者。
  • 患者均接受新辅助治疗后根治性切除及D3淋巴结清扫,按标准化三站方案送检区域淋巴结。

主要发现

  • 术后病理显示25.8%(25/97)患者仍存在淋巴结转移。
  • 16.5%(16/97)患者转移局限于S1站,9.3%(9/97)累及S2站,无患者出现S3站转移。
  • ypT3~4期患者淋巴结转移率38.5%,高于ypT1~2期的14.3%和ypT0期的5.9%(P=0.003)。
  • S1站转移组5年DFS率约100%,S2站转移组为38.9%(95%CI:16.2%~93.1%),Log-rank检验P=0.003。
  • Cox比例风险模型显示转移淋巴结部位是DFS的预后因素(HR=19.80,P=0.004)。

关键数值与推荐

  • 对于新辅助治疗后中低位LARC患者,若无淋巴结转移相关危险因素且无明确肠系膜下动脉根部淋巴结转移证据,可酌情不行肠系膜下动脉根部淋巴结清扫。

临床怎么用

  • 新辅助治疗后中低位LARC的淋巴结转移主要位于S1和S2站,S3站转移未见,可据此考量肠系膜下动脉根部淋巴结清扫的必要性。
  • 转移淋巴结分布位置与DFS显著相关,S2站转移者预后较差,应加强术后随访与辅助治疗决策。

局限性

  • 本研究为单中心回顾性病例系列分析,样本量有限,结论需更大队列验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the spatial distribution characteristics of metastatic lymph nodes after neoadjuvant therapy in patients with mid-low locally advanced rectal cancer (LARC) and its impact on prognosis. Methods: This is a retrospective case series analysis. The clinical and pathological data of 97 patients with mid-low LARC who received neoadjuvant therapy followed by radical resection managed a single clinical team at the Department of Colorectal Surgery, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, between January 2016 and June 2025 were retrospectively analyzed. There were 59 males (60.8%) and 38 females (39.2%), with an age of (57.5±9.9) years (range: 34 to 77 years). All patients underwent D3 lymph node dissection during surgery, and regional lymph nodes were examined according to a standardized three-station protocol: first station (S1, pararectal lymph nodes), second station (S2, intermediate lymph nodes), and third station (S3, main lymph nodes). Patients were stratified according to tumor location, neoadjuvant therapy regimen and ypT stage for analyzing the spatial distribution patterns of metastatic lymph nodes. Survival analysis was performed using the Kaplan-Meier method, and potential prognostic factors for patient survival were assessed with the Cox proportional hazards model. Results: Postoperative pathological examination showed that 25.8% (25/97) of LARC patients still had lymph node metastasis (LNM) after neoadjuvant therapy. LNM was confined to S1 in 16.5% (16/97) of patients, involved S2 in 9.3% (9/97) of patients, and no patient had S3 LNM. The LNM rate among patients with ypT3-4 disease (38.5%) was significantly higher than those in patients with ypT1-2 (14.3%) and ypT0 (5.9%) disease (P=0.003). Survival analysis demonstrated that disease-free survival (DFS) of patients with S1 LNM was superior to that of patients with S2 LNM, with a statistically significant difference (Log-rank test, P=0.003). The estimated 5-year DFS rate for the S1 LNM group was approximately 100%, whereas the 5-year DFS rate for the S2 LNM group was 38.9% (95%CI: 16.2% to 93.1%). Cox proportional hazards model analysis revealed that the site of metastatic lymph nodes (HR=19.80, P=0.004) was a prognostic factor for DFS. Conclusions: The LNM rate in patients with mid-low LARC decreases after neoadjuvant therapy, with metastases predominantly concentrated in the S1 and S2 regions. For patients with mid-low LARC after neoadjuvant therapy who have no LNM-related risk factors and no definitive evidence of LNM at the root of the inferior mesenteric artery, lymph node dissection at the root of the inferior mesenteric artery may be reasonably omitted. The distribution site of metastatic lymph nodes is a potential prognostic factor and could be incorporated into the TNM staging system to refine staging and improve prognostic accuracy. 目的: 探讨中低位局部进展期直肠癌(LARC)患者新辅助治疗后转移淋巴结的空间分布特征及其对患者预后的影响。 方法: 本研究为回顾性病例系列研究。回顾性分析2016年1月至2025年6月于中国医学科学院北京协和医学院肿瘤医院结直肠外科单一治疗组接受新辅助治疗,并行根治性切除的97例中低位LARC患者的临床和病理学资料。男性59例(60.8%),女性38例(39.2%);年龄(57.5±9.9)岁(范围:34~77岁)。所有患者术中接受D3淋巴结清扫,并按标准化三站方案送检区域淋巴结:第一站(S1,肠旁淋巴结)、第二站(S2,中间淋巴结)和第三站(S3,主淋巴结)。分别按肿瘤部位、新辅助治疗方案和ypT分期将患者分层,分析新辅助治疗后的中低位LARC转移淋巴结的空间分布规律。采用Kaplan-Meier法进行生存分析,通过Cox比例风险模型评估患者生存的潜在预后因素。 结果: 术后病理学检查结果显示,25.8%(25/97)的LARC患者在接受新辅助治疗后仍存在淋巴结转移(LNM)。16.5%(16/97)的患者LNM局限于S1,9.3%(9/97)的患者累及S2,所有患者未出现S3 LNM。ypT3~4期患者的LNM率(38.5%)高于ypT1~2期(14.3%)和ypT0期(5.9%)患者(P=0.003)。生存分析结果显示,S1 LNM患者整体无病生存(DFS)优于S2 LNM患者,差异有统计学意义(Log-rank检验,P=0.003)。其中,S1 LNM组5年DFS率估计值约为100%,而S2 LNM组患者5年DFS率为38.9%(95%CI:16.2%~93.1%)。Cox比例风险模型分析结果显示,转移淋巴结部位(HR=19.80,P=0.004)是患者DFS的预后因素。 结论: 中低位LARC患者新辅助治疗后LNM率降低,主要集中于S1和S2区域。对于新辅助治疗后的中低位LARC患者,若无LNM相关危险因素,且无明确肠系膜下动脉根部LNM证据,可酌情不行肠系膜下动脉根部淋巴结清扫。转移淋巴结的分布位置是患者的潜在预后因素,可将其纳入TNM分期系统以改良分期,提高预后评估的准确性。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lu SB, Yang WJ, Chen GJ, et al. [Spatial distribution characteristics and clinical significance of metastatic lymph nodes after neoadjuvant therapy for locally advanced mid-low rectal cancer]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 42951855. doi:10.3760/cma.j.cn112139-20260316-00107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。